Syntrax LipoKinetix Liver AERs Necessitate Product Removal – FDA
This article was originally published in The Tan Sheet
Executive Summary
LipoKinetix should be withdrawn from the market due to reports linking the weight-loss supplement to "at least six" cases of serious liver injury, FDA states in a 1Nov. 19 letter to Chaufee, Mo.-based Syntrax Innovations
You may also be interested in...
FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban
FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg
FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban
FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg
FDA’s McClellan Touts Scientific Analysis As Part Of Ephedra Ban
FDA Commissioner Mark McClellan, MD/PhD, said the "framework" for the outright ban of ephedra will be based on substantive scientific evidence as the agency prepares to publish the reg